[Acoustic follow-up of nocturnal bronchial obstruction therapy].
Long acting beta 2-agonists belong to the basic therapy of COPD. Especially patients with nocturnal respiratory problems may benefit from this therapy. Long term recording of lung sounds is a new method for quantitative measurements of bronchial obstructions. In combination with polysomnography an evaluation of cardiorespiratory parameters and sleep structure is possible. A total of 10 patients (8 male and 2 female) with moderate COPD (FEV1 58 +/- 11 %) and signs of bronchial obstruction were investigated. The combination of acoustic long term recording and polysomnography was done for 2 or 3 nights without and under therapy (long acting beta 2-agonist, 50 microg Salmeterol). In all patients we could find nocturnal bronchial obstruction events. Nocturnal wheezing time was reduced during therapy to 33 +/- 17 % (1. therapy night, n. s.) compared to 49 +/- 30 % without therapy (control night) and to 17 +/- 17 % (2. therapy night, n = 6, p < 0.05) vs. 51 +/- 30 % (control night, n = 6). Sleep efficiency and REM sleep increased (n. s.) under therapy, deep sleep stages NREM III/IV were nearly the same. Acoustic long term monitoring confirms the reduction of nocturnal bronchial obstructions under therapy with beta 2-agonists. A better sleep quality may be expected from the improvement of the respiratory situation during sleep.
Koehler
U
U
Klinik für Innere Medizin, SP Pneumologie, Intensiv- und Schlafmedizin, Philipps-Universität Marburg. koehleru@mailer.uni-marburg.de
Gross
V
V
Reinke
C
C
Penzel
T
T
Vogelmeier
C
C
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017286:Polysomnography; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D000068299:Salmeterol Xinafoate; D020181:Sleep Apnea, Obstructive / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D013018:Sound Spectrography
D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D000068299:Salmeterol Xinafoate; D000420:Albuterol
Akustische Therapieverlaufskontrolle nächtlicher Bronchialobstruktionen.